Olpha

What Olpha does

Olpha, legally Akciju sabiedrība "Olpha" and headquartered at Rūpnīcu iela 5, Olaine, Latvia, is a vertically integrated pharmaceutical manufacturer with more than 50 years of operating history (formerly branded AS Olainfarm, rebranded to Olpha in 2024). The company operates five group companies and distributes through more than 60 markets primarily across the Baltics, CIS, Central Asia and Southeast Europe, with country-specific websites in 15 of these markets. Olpha's stated workforce of 850+ specialists supports a portfolio spanning 60+ finished dosage forms, 25 active pharmaceutical ingredients, and more than 20 intermediates across 10 therapeutic groups (urology, hematology, cardiology, allergology, neurology, oncology, pain and inflammation, anesthesiology, anti-infectives, gastroenterology, endocrinology, pulmonology).

The company's product and service platform rests on three layers: (i) in-house drug development and API/intermediate manufacturing; (ii) finished dosage form production, including dietary supplements; and (iii) business-to-business services encompassing contract manufacturing (Līgumražošana), pharmaceutical co-development, out-licensing, and product governance, complemented by pharmacovigilance and the gated Open Olpha training portal for healthcare professionals. Distribution combines direct B2B partner contracts, country-specific distribution networks in 60+ markets, and pharmacy/healthcare institution supply, while marketing relies on localized websites, direct healthcare-professional outreach, the Open Olpha e-learning portal, and press activity.

Olpha generates revenue through five mechanisms: one-time license sales of proprietary pharmaceutical products, professional services revenue from contract manufacturing and co-development engagements, licensing royalties from out-licensing arrangements, and hardware-equivalent sales of nutritional supplements manufactured for partners. Pricing is not publicly disclosed and is negotiated bilaterally with B2B partners. Recent capital commitments include a EUR 5.84 million production facility expansion announced in June 2026 to manufacture new products, alongside an explicit strategy to export drug R&D services internationally. No revenue, funding rounds, or ownership disclosures appear in the available source material, leaving the financial profile of the company unverified.

Name

Olpha

Legal name

Akciju sabiedrība "Olpha"

Website

https://olpha.eu

Company type

Private

Founded year

1972

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Olpha is a Latvian pharmaceutical manufacturer (Akciju sabiedrība) operating from Olaine with 850+ specialists and 50+ years of history, producing APIs, intermediates, and finished dosage forms across 10 therapeutic areas for distribution in 60+ markets and B2B contract manufacturing, co-development, and out-licensing partners.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Pharmaceutical manufacturing
• Contract manufacturing
• Active pharmaceutical ingredients
• Drug formulation
• Pharmaceutical licensing

Headquarters

HQ city

Olaine

HQ country

Latvia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical product sales: Sale of proprietary pharmaceutical products across 10 therapeutic areas including urology, hematology, cardiology, allergology, neurology, oncology, pain & inflammation, anesthesiology, anti-infectives, gastroenterology, endocrinology, and pulmonology
2. Contract manufacturing (Līgumražošana): Contract manufacturing of finished dosage forms, active pharmaceutical ingredients, and intermediates for business partners
3. Pharmaceutical co-development: Joint pharmaceutical development services for partners seeking to develop new drugs or formulations
4. Pharmaceutical out-licensing: Licensing of pharmaceutical products to distribution and sales partners
5. Nutritional supplement manufacturing: Manufacturing of dietary supplements for business partners

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Olpha manufactures and sells finished pharmaceutical dosage forms, active pharmaceutical ingredients (APIs), and intermediates across 10 therapeutic areas. Beyond its own product portfolio, the company provides contract manufacturing, pharmaceutical co-development, out-licensing, and dietary supplement manufacturing services to business partners. Products are sold under the Olpha brand and through licensed partners in 60+ markets across the Baltics, CIS, Central Asia, and Southeast Europe.

Product overview

Olpha is a leading pharmaceutical manufacturer in the Baltic region operating as a single unified portfolio company. The product portfolio encompasses over 60 finished dosage forms, 25 active pharmaceutical ingredients (APIs), and more than 20 intermediates across 10 therapeutic areas (Urology, Hematology, Cardiology, Allergology, Neurology, Oncology, Pain & Inflammation, Anesthesiology, Anti-infectives, Gastroenterology, Endocrinology, Pulmonology). The company operates with 850+ specialists and 50+ years of experience, offering both products and services including contract manufacturing, pharmaceutical co-development, out-licensing, and product governance. A complementary digital platform, Open Olpha, provides training and education services for healthcare professionals.

Differentiator

Problem solved

Functional benefit

Products and services

• Finished Dosage Forms Over 60 finished pharmaceutical dosage forms covering urology, hematology, cardiology, allergology, neurology, oncology, pain & inflammation, anesthesiology, anti-infectives, gastroenterology, endocrinology, and pulmonology, sold to business partners and through distribution networks.
• Active Pharmaceutical Ingredients (APIs) 25 active pharmaceutical ingredients produced for downstream formulation of finished pharmaceutical products, supplied to pharmaceutical manufacturers and partners.
• Pharmaceutical Intermediates More than 20 pharmaceutical intermediates supporting the manufacture of APIs and finished dosage forms, supplied to industry partners.
• Dietary Supplements Nutritional supplements manufactured by Olpha for health and wellness support, produced for business partners under contract manufacturing arrangements.
• Pharmaceutical Contract Manufacturing Contract manufacturing services for finished dosage forms, APIs, and intermediates delivered to pharmaceutical business partners, backed by an 850+ specialist team and 50+ years of manufacturing experience.
• Pharmaceutical Co-development Joint pharmaceutical development services provided to partners seeking to develop new drug formulations or products, leveraging Olpha's R&D and manufacturing capabilities.
• Pharmaceutical Out-licensing Licensing services for Olpha's pharmaceutical products to enable distribution and sales partners to commercialize them in target markets.
• Product Governance Services Product management and governance services for pharmaceutical portfolios, supporting partners with lifecycle management of pharmaceutical products.
• Pharmacovigilance Services Drug safety monitoring and adverse drug reaction reporting services supporting Olpha's pharmaceutical products and partner portfolios across markets.

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered supporting and minor.

• Proxima Research s.r.o.supportingTechnology or IntegrationProxima Research s.r.o. (Slovakia) serves as a data processor for Olpha, providing technical data storage, system management, and electronic communication distribution for healthcare professional engagement. Data may be transferred outside EU/EEZ under standard contractual clauses.
• SIA Centrālā laboratorijaminorStrategic or Co-development PartnerOlpha cooperates with SIA Centrālā laboratorija in projects aimed at increasing knowledge and experience of students and teaching staff in pharmaceutical and chemistry study programs, as part of its student scholarship program and educational initiatives.
• Latvian Association of Chemical and Pharmaceutical Entrepreneurs (Latvijas Ķīmijas un farmācijas uzņēmēju asociācija)minorStrategic or Co-development PartnerOlpha cooperates with the Latvian Association of Chemical and Pharmaceutical Entrepreneurs in initiatives supporting chemistry and pharmacy industry development, including student scholarship programs.
• Latvian universitiesminorStrategic or Co-development PartnerOlpha partners with Latvian higher education institutions in projects focused on increasing knowledge and experience of students and teaching staff in pharmaceutical and chemistry study programs, including student scholarship programs.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• KRKA: Slovenian generic pharmaceutical manufacturer with strong presence in CEE, CIS, and Central Asia, producing APIs, intermediates, and finished dosage forms. Highly comparable to Olpha in regional footprint and vertically integrated model.
• Zentiva: Central and Eastern European generic pharmaceutical manufacturer offering APIs, FDFs, and CDMO services across multiple therapeutic areas. Closely comparable to Olpha in geographic focus, vertical integration, and product breadth.
• Polpharma: Polish generics and API manufacturer serving European and CIS markets with FDFs and active substances. Comparable regional positioning and API/FDF combination.
• Gedeon Richter: Hungarian-headquartered pharmaceutical company with APIs, generics, and branded pharmaceuticals spanning multiple therapeutic areas. Comparable on CEE origin, vertical integration, and global distribution model.
• Alvogen: US-headquartered but with strong Central and Eastern European and CIS generics footprint, including the Balkans and Baltics. Comparable for CEE/CIS generics distribution model.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with broad API and FDF capabilities across virtually all therapeutic areas. Competes with Olpha in generic FDFs and APIs at global scale.
• Viatris: Global generics and specialty manufacturer with extensive CEE/CIS presence formed via Mylan-Upjohn merger. Comparable generics portfolio with overlapping therapeutic areas.
• Hikma Pharmaceuticals: UK-listed generics and injectables manufacturer serving MENA, Europe, and the US. Comparable vertically integrated generics manufacturing with CDMO exposure.
• Stada Arzneimittel: Germany-based European generics and consumer healthcare major with multi-therapeutic area portfolio. Comparable product breadth and European generics focus.
• Sandoz (Novartis): Global generics and biosimilars business spun out from Novartis, active across APIs, generics, and CDMO. Comparable multi-therapeutic and vertically integrated model at much greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/OlphaLatvia
• LinkedInlinkedin.com/company/olphaglobal

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Olpha